Skip to main content
OpenTrials

Clinical trial condition

Myelodysplastic-Myeloproliferative Diseases

Explore clinical trials studying Myelodysplastic-Myeloproliferative Diseases. Study availability and eligibility vary by location and protocol.

384 public trials 62 recruiting studies
Refine in advanced search Browse all conditions

Myelodysplastic-Myeloproliferative Diseases trial results

Active, Not Recruiting

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

NCT03190915

Conditions
Bone Marrow Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +22 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Downey Medical Center Downey, California, United States
View all 57 locations
View Trial Details
Active, Not Recruiting

Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

NCT02530034

Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Crisis, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, +31 more
Locations
  • Augusta University Augusta, Georgia, United States
  • Montefiore Medical Center, Albert Einstein College of Medicine The Bronx, New York, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • Huntsman Cancer Institute Salt Lake City, Utah, United States
View Trial Details
Active, Not Recruiting

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

NCT02935361

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myelomonocytic Leukemia, +14 more
Locations
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • University of Maryland Medical Center Baltimore, Maryland, United States
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976

Conditions
Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +24 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
View all 294 locations
View Trial Details
Active, Not Recruiting

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

NCT03722407

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myelomonocytic Leukemia, +11 more
Locations
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Weill Medical College of Cornell University New York, United States
View Trial Details
Active, Not Recruiting

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

NCT04802161

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, +19 more
Locations
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • University of Kansas Cancer Center Kansas City, Kansas, United States
  • University of Kansas Hospital-Westwood Cancer Center Westwood, Kansas, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details

Related conditions